Type 2-immunity represents the typical adaptive response to allergen exposure in atopic
individuals. It mainly involves Th2 cells and immunoglobulin E, as the main orchestrators of …

Abstract We reviewed 24 'real‐life'effectiveness studies of omalizumab in the treatment of
severe allergic asthma that included 4117 unique patients from 32 countries with significant …

Background Clinical characteristics of the international population with severe asthma are
unknown. Intercountry comparisons are hindered by variable data collection within regional …

Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by
accredited centers on severe asthma. Objective To analyze epidemiological, clinical …

Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of
outcomes in real-world clinical practice is needed to provide a complete understanding of …

Background After the approval of omalizumab for severe allergic asthma, a total of 25
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …

A small subgroup of patients with asthma suffers from severe disease that is either partially
controlled or uncontrolled despite intensive, guideline-based treatment. These patients have …

Objective: This study sought to characterize the epidemiologic, clinical, humanistic, and
economic burden of patients with asthma uncontrolled by GINA Steps 4 or 5 treatment …

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the
US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma …